The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Linzess label, and added Drugs@FDA approval records for Linzess and generic linaclotide. 12
What this version reported
Large randomized, placebo-controlled trials described in the label support its adult uses. The label carries a boxed warning: it is contraindicated in children younger than 2 because of a risk of serious dehydration.↗
Reader guide in this version
Key takeaway
Linaclotide is a lab-made peptide related to guanylin and uroguanylin, natural gut hormones, and is the active ingredient in AbbVie’s Linzess.1,2 It is FDA-approved for irritable bowel syndrome with constipation in adults and children aged 7 and older, chronic idiopathic constipation in adults, and functional constipation in children aged 2 and older.1 Its adult approvals rest on large randomized, placebo-controlled trials of about 600 to 800 adults each described in the label.1 The label carries a boxed warning: it is contraindicated in children younger than 2 because it caused deaths from dehydration in young mice.1
At a glance
- What it is
- A guanylate cyclase-C agonist that the label says acts locally on the lining of the intestine.1
- FDA status
- FDA-approved. Drugs@FDA lists Linzess with an original approval date of August 30, 2012. The label carries a boxed warning about serious dehydration in children younger than 2.1,2
- Human evidence
- Large randomized, placebo-controlled trials in adults and randomized trials in children, described in the label.1
- Evidence strength
- Large randomized human trials
What is linaclotide?
Linaclotide is a lab-made peptide that the label describes as structurally related to guanylin and uroguanylin, hormones made in the gut.1
Drugs@FDA lists it as the active ingredient of Linzess, from AbbVie, and of generic linaclotide applications approved in 2021 and 2023.2,3,4
How does linaclotide work?
The label states that linaclotide and its active breakdown product activate guanylate cyclase-C on the surface of the intestinal lining. This increases a signalling molecule, cGMP, which draws chloride, bicarbonate and fluid into the intestine and speeds transit.1
The label also states that in animal models linaclotide reduced intestinal pain and the activity of pain-sensing nerves.1
What do human studies show?
The label describes two randomized, double-blind, placebo-controlled trials in adults with irritable bowel syndrome with constipation, with 800 and 804 participants. In both, a statistically significantly higher proportion of people responded to linaclotide than to placebo, based on combined pain and bowel-movement measures.1
Two further trials in adults with chronic idiopathic constipation, with 642 and 630 participants, and randomized trials in children are also described in the label.1
Diarrhea was the most common adverse reaction: in the adult irritable bowel syndrome trials it affected 20% of people taking linaclotide and 3% on placebo, and was severe in 2%, according to the label.1
What the evidence base contains
- Large randomized human trial Two randomized, double-blind, placebo-controlled trials in irritable bowel syndrome with constipation (NCT00948818 and NCT00938717), with 800 and 804 adults evaluated for efficacy.1
- Large randomized human trial Two randomized, double-blind, placebo-controlled trials in chronic idiopathic constipation, with 642 and 630 adults evaluated for efficacy.1
- Controlled human trial A 12-week randomized, double-blind, placebo-controlled trial in 328 children aged 6 to 17 with functional constipation.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is linaclotide FDA-approved?
Yes. Drugs@FDA lists Linzess, application NDA202811, with an original approval date of August 30, 2012, and generic linaclotide applications approved on February 9, 2021 and February 7, 2023.2,3,4
The Linzess label cited here (DailyMed SPL version 39, published June 1, 2026) states that it is indicated for irritable bowel syndrome with constipation in adults and children aged 7 and older, chronic idiopathic constipation in adults, and functional constipation in children aged 2 and older.1
The label carries a boxed warning: linaclotide is contraindicated in children younger than 2, because in studies in newborn mice it caused deaths due to dehydration.1
The label also states that it is contraindicated in people with known or suspected mechanical blockage of the gut, and warns about diarrhea, which can be severe.1
What is still unknown?
Its safety in children younger than 2, for whom the label says it is contraindicated.1
Its long-term effects: the main adult trials lasted 12 to 26 weeks.1
Sources for this version
- 1LINZESS (linaclotide) capsule · SPL version 39 · published 2026-06-01 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA202811 · original submission status AP · 2012-08-30 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application ANDA209564 · original submission status AP · 2021-02-09 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application ANDA209611 · original submission status AP · 2023-02-07 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026